Author

Michal Zimmermann

Mount Sinai HospitalORCID 0000-0002-9955-1675Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Michal Zimmermann1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioinformatics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1

Frequent Co-Authors

Alejandro Álvarez-QuilóniD· 2 shared Artur VelosoiD· 2 shared Daniel DurocheriD· 2 shared Jordan T.F. Young· 2 shared Julian Bowlan· 2 shared Li Li· 2 shared Nancy LaterreuriD· 2 shared Stephen J. Morris· 2 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alejandro Álvarez-QuilónORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CRISPR-enabled genetic screens identify synthetic lethal targets across frequently altered cancer drivers

Jessica Desjardins, Julian Bowlan, Cynthia Bernier, Srishti Jain, Théo Goullet de Rugy, David Gallo, Mark E. Orcholski, Nancy Laterreur, Abira Rajah, Joshua Miller, Jennifer A. Lafontaine, Vivek Bhaskaran, Li Li, Alexanda K. Ling, Jesse H. Leblanc, , Jordan T.F. Young

This study identifies synthetic lethal interactions between cancer drivers and tractable targets using CRISPR screens and cancer dependency data, offering new drug targets for therapy.

bioRxiv · Jan 25, 2026 · PreprintCancer Biology

A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma

Isabel Soria‐Bretones, Matias Casás‐Selves, Elliot Goodfellow, Li Li, Cathy Caron, Ariya Shiwram, Hye‐Yeon Kim, Danielle Henry, Nancy Laterreur, Julian Bowlan, Alejandro Álvarez-Quilón, Frédéric Vallée, Artur Veloso, Jordan T.F. Young, Marc L. Hyer, , Michal Zimmermann

This study shows neuroblastoma cells are hypersensitive to PLK4 inhibitor RP-1664 due to dual mechanisms of centriole loss and amplification, leading to cell death.

bioRxiv · Feb 15, 2025 · PreprintCancer Biology

Identifying chemogenetic interactions from CRISPR knockout screens with drugZ

Medina Colic, Gang Wang, Michal Zimmermann, Keith Mascall, Megan McLaughlin, Lori Bertolet, W. Frank Lenoir, Jason Moffat, Stéphane Angers, Daniel Durocher, Traver Hart

drugZ identifies chemogenetic interactions from CRISPR screens, finding more homologous recombination repair pathway genes and confirming KEAP1 loss as a resistance factor for ERK inhibitors.

bioRxiv · Mar 11, 2019 · PreprintBioinformatics